IP Library Granted Patent US 11,229,792
Granted Patent B2
US 11,229,792 · App. 16/670,712 · Granted Jan 25, 2022

Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods

Inventors: Konstantinos Alataris (Belmont, CA); Andre B. Walker (Monte Sereno, CA); Jon Parker (San Jose, CA)
Assignee: Nevro Corp.
A61N1/36071A61N1/3615A61N1/36021A61N1/36132A61N1/36171A61N1/36178A61N1/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,792
App. No.
16/670,712
Granted
Jan 25, 2022
Kind
B2
Abstract

Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods are disclosed. A representative method in accordance with an embodiment of the disclosure includes creating a therapeutic effect and a sensation in a patient by delivering to the patient first pulses having a first set of first signal delivery parameters and second pulses having a second set of second signal delivery parameters, wherein a first value of at least one first parameter of the first set is different than a second value of a corresponding second parameter of the second set, and wherein the first pulses, the second pulses or both the first and second pulses are delivered to the patient's spinal cord.

Claims (15)

1. A method for configuring a patient treatment system to deliver a therapy signal to a target neural population at a patient's spinal cord, the method comprising:

programming a signal generator of the patient treatment system to:

generate bursts of low frequency pulses comprising at least one pair of pulses having the same polarity, wherein the at least one pair of pulses has a frequency between 2 Hz and 1.2 kHz;

generate high frequency pulses between sequential bursts of the low frequency pulses, wherein the high frequency pulses have a frequency between 1.5 kHz and 50 kHz; and

deliver the bursts of low frequency pulses and the high frequency pulses to the target neural population in cycles, wherein the high frequency pulses do not generate paresthesia when delivered to the target neural population.

2. The method of claim 1 , further comprising programming the signal generator to deliver the bursts of low frequency pulses and the high frequency pulses to the target neural population in cycles such that delivery of the bursts of low frequency pulses does not temporally overlap with delivery of the high frequency pulses.

3. The method of claim 1 , wherein the low frequency pulses and the high frequency pulses are bi-phasic pulses.

4. The method of claim 1 , wherein each low frequency pulse has a pulse width within a pulse width range from 10 microseconds to 1,000 microseconds.

5. The method of claim 1 , wherein each high frequency pulse has a pulse width within a pulse width range from 10 microseconds to 333 microseconds.

6. The method of claim 1 , wherein the low frequency pulses have a first pulse width and the high frequency pulses have a second pulse width shorter than the first pulse width.

7. The method of claim 1 , wherein the high frequency pulses have a frequency between 5 kHz and 15 kHz.

8. The method of claim 1 , wherein an amplitude of the low frequency pulses is the same as an amplitude of the high frequency pulses.

9. The method of claim 1 , wherein the bursts of low frequency pulses induce paresthesia in the patient.

10. The method of claim 1 , further comprising programming the signal generator to direct the bursts of low frequency pulses to a first electrode of the patient treatment system and the high frequency pulses to a second electrode of the patient treatment system different than the first electrode.

11. The method of claim 1 , further comprising programming the signal generator to direct the bursts of low frequency pulses and the high frequency pulses to a common electrode of the patient treatment system.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2020
From: ALATARIS, KONSTANTINOS; WALKER, ANDRE B; PARKER, JON
To: NEVRO CORP.
Reel/Frame 053618/0330 →
Continuity (4)
Continuation 14292671 · May 30, 2014
Continuation 12765685 · Apr 22, 2010
Provisional Application 61171790 · Apr 22, 2009
Related Publication 20200171309A1 · Jun 4, 2020
Cited By (6)
US 12,280,256 US 12,285,611 US 12,390,645 US 12,465,776 US 12,491,365 US 12,558,547